490 related articles for article (PubMed ID: 27003914)
1. Current Status: Site-Specific Antibody Drug Conjugates.
Schumacher D; Hackenberger CP; Leonhardt H; Helma J
J Clin Immunol; 2016 May; 36 Suppl 1():100-7. PubMed ID: 27003914
[TBL] [Abstract][Full Text] [Related]
2. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
3. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
[TBL] [Abstract][Full Text] [Related]
4. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
6. Antibody conjugates with unnatural amino acids.
Hallam TJ; Wold E; Wahl A; Smider VV
Mol Pharm; 2015 Jun; 12(6):1848-62. PubMed ID: 25898256
[TBL] [Abstract][Full Text] [Related]
7. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
9. Linker technologies for antibody-drug conjugates.
Nolting B
Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Development of Site-Specific Antibody-Drug Conjugation.
Zhou Q; Kim J
Anticancer Agents Med Chem; 2015; 15(7):828-36. PubMed ID: 25731178
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Antibody-Drug Conjugation Using Microbial Transglutaminase.
Dickgiesser S; Deweid L; Kellner R; Kolmar H; Rasche N
Methods Mol Biol; 2019; 2012():135-149. PubMed ID: 31161507
[TBL] [Abstract][Full Text] [Related]
12. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
13. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system.
Zimmerman ES; Heibeck TH; Gill A; Li X; Murray CJ; Madlansacay MR; Tran C; Uter NT; Yin G; Rivers PJ; Yam AY; Wang WD; Steiner AR; Bajad SU; Penta K; Yang W; Hallam TJ; Thanos CD; Sato AK
Bioconjug Chem; 2014 Feb; 25(2):351-61. PubMed ID: 24437342
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
[TBL] [Abstract][Full Text] [Related]
15. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
16. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
Campos MP; Konecny GE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
[TBL] [Abstract][Full Text] [Related]
17. Physical and Chemical Stability of Antibody Drug Conjugates: Current Status.
Ross PL; Wolfe JL
J Pharm Sci; 2016 Feb; 105(2):391-397. PubMed ID: 26869406
[TBL] [Abstract][Full Text] [Related]
18. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
19. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
20. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
